BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It develops BGE-102, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.

BioAge Labs, Inc.

Some low‑priced stocks are drawing attention from Wall Street thanks to their growth plans and strong sector trends. These names trade under $10 bu...

3 Stocks Under $10 With Over 100% Upside, According to Analysts

Analysts have been eager to weigh in on the NA sector with new ratings on BioAge Labs, Inc. (BIOA) and Fiserv (FISV). BioAge Labs, Inc. (BIOA) In a...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BIOA	$9.59	+0.95%	314.85K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BIOA	$9.59	+0.9%	314.85K
3
4
5
6

BIOA

Get BioAge Labs, Inc. Data in Excel

Get BioAge Labs, Inc. Data in Excel